HUTCHMED Closes GSK License for HMPL-A830 Outside China With $110 Million Upfront

HUTCHMED (China) Limited closed its exclusive development and license agreement with a GSK plc subsidiary for HMPL-A830, a KRAS-EGFR antibody-targeted therapy conjugate, outside China. The company expects $110 million upfront and up to $1.185 billion in milestones, GlobeNewswire reported.

HUTCHMED Hands GSK Ex-China Rights to HMPL-A830

The agreement grants the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830. The candidate pairs a KRAS small molecule inhibitor payload with an anti-EGFR antibody, designed to deliver the inhibitor to EGFR-expressing tumors while blocking EGFR and KRAS signaling. Colorectal, pancreatic and lung cancers have the highest incidence of KRAS-altered tumors, according to the company.

HUTCHMED Limited is responsible for the global Phase I development program, and the GSK subsidiary will handle all subsequent clinical development and commercialization in its territory. The Phase Ia part of a global trial in patients with unresectable, advanced or metastatic solid tumors began in September 2026 in China and the US, under clinicaltrials.gov identifier NCT07718581. TradingView reported that GSK leads later-stage development and commercialization. GSK is a global biopharma company.

HUTCHMED's September 2026 Deal Run-Up

On September 3, 2026, HUTCHMED entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, with potential value up to $1.3 billion, MarketBeat reported. Pharmaceutical Technology reported the same day that GSK licensed the solid tumour conjugate for $110 million upfront, with global rights and $1.185 billion in milestones, potentially reaching $1.295 billion. On September 24, 2026, HUTCHMED said it would present new clinical data from two Phase III studies at the ESMO Congress 2026 in Madrid, including results from the SAFFRON and SANOVO studies, FinancialContent Business Page reported.

Hansoh and Regeneron Partner Deals

Hansoh Pharmaceutical and Roche entered a partnership and licensing deal worth over $15 billion covering antibody-drug conjugate programs, EIN Presswire reported on October 19, 2026. Hansoh receives an upfront $400 million and a first anniversary payment of $110 million, with further milestone payments. On October 14, 2026, PRESSBEE reported that Kiniksa Pharmaceuticals is among the top biotech stocks to watch, boosted by its exclusive agreement with Regeneron.

HUTCHMED's US Filing for ORPATHYS Plus TAGRISSO

On September 29, 2026, AstraZeneca submitted an FDA new drug application for ORPATHYS plus TAGRISSO to treat MET-driven EGFR-mutated lung cancer after EGFR-TKI progression, FinancialContent Business Page reported.